Navigation Links
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Date:11/14/2012

tatements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. 


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at Upcoming Healthcare and Investor Conferences
2. OncoSec Granted New Patent from China
3. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
4. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
7. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
8. OncoSec Medical Issues Letter to Shareholders
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
11. Rochester Medical Reports Record Fourth Quarter and Fiscal Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... New York, New York (PRWEB) July 13, 2014 ... much to bring attention to the cancer risks associated ... a chance to tell their story to federal regulators, ... of a U.S. Food & Drug Administration (FDA) ... Liebhard LLP reports. According to the Rochester Democrat ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... TX (PRWEB) July 13, 2014 The Pearland, ... children ranging in age from four months to 12 years ... and karate classes to birthday parties and Summer Camps, is ... Little Gym of Pearland after spending over six ... of roles, including Gym Director. , Berry has over ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... WEST CONSHOHOCKEN, Pa., May 1 Cadient Group, ... announced today it has appointed Barbara Dowling as ... in the healthcare,vertical on both the client and ... the digital channel to address business critical,issues. In ...
... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced the dates and ... and Annual Meeting of Shareholders., First Quarter Results ... a.m. (ET) Labopharm will host a conference,call to discuss ... first quarter 2008 financial results via news release at,approximately ...
... (Nasdaq: GTIV ), the nation,s leading provider of,comprehensive home ... quarter ended March 30, 2008:, (Logo: ... to $323.7 million versus the first quarter ... 13% to $7.7 million, or $0.27 per diluted share, ...
... intensive care will experience delusions or hallucinations, which put ... to a new study of childrens experiences in a ... which appears in the first issue for May of ... published by the American Thoracic Society, is believed to ...
... may also mask its severity in standard tests, according to ... women with a range of body mass indexes (BMIs). , ... comparative difference in how the airways and lungs respond to ... , The research is reported in the first issue for ...
... Christopher,s Hospital for Children and Independence Blue,Cross (IBC) ... principle,on terms of new contracts. They have extended ... multi-year contracts. Hahnemann and St.,Christopher,s are both part ... network of hospitals. The parties will continue to ...
Cached Medicine News:Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 3Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 4Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 5Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 6Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 7Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 8Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 9Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 10Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 11Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 12Health News:Haunted by hallucinations: Children in the PICU traumatized by delusions 2Health News:Obesity worsens impact of asthma 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 3
... represents an rhBMP-2 (recombinant human bone morphogenetic ... absorbable collagen sponge (ACS) carrier. The Infuse ... indicated for spinal fusion procedures in skeletally ... at one level from L4-S1, who may ...
... Graftech cervical dowels are ... to graft expulsion and improve ... allows immediate red blood cell ... Grafton DBM gel into the ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Cranial Fixation Systems incorporate a great ... by surgeons and surgical staff. Additionally, ... be either shaped on the spot ... pre-measured, cut, bent and shaped implant ...
Medicine Products: